JP7548567B2 - Ｉｌ－３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用 - Google Patents

Ｉｌ－３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用 Download PDF

Info

Publication number
JP7548567B2
JP7548567B2 JP2020560900A JP2020560900A JP7548567B2 JP 7548567 B2 JP7548567 B2 JP 7548567B2 JP 2020560900 A JP2020560900 A JP 2020560900A JP 2020560900 A JP2020560900 A JP 2020560900A JP 7548567 B2 JP7548567 B2 JP 7548567B2
Authority
JP
Japan
Prior art keywords
composition
fibrosis
subject
mbv
clause
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020560900A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021523103A (ja
JP2021523103A5 (https=
Inventor
スティーブン フランシス バディラク，
ジョージ エス． ハッシー，
ヘス ターンクイスト，
ジェンナ リン ジキ，
チュアン リウ，
ジョンチャン ジャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pittsburgh
Original Assignee
University of Pittsburgh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pittsburgh filed Critical University of Pittsburgh
Publication of JP2021523103A publication Critical patent/JP2021523103A/ja
Publication of JP2021523103A5 publication Critical patent/JP2021523103A5/ja
Priority to JP2024140826A priority Critical patent/JP2024159910A/ja
Application granted granted Critical
Publication of JP7548567B2 publication Critical patent/JP7548567B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5184—Virus capsids or envelopes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/3633—Extracellular matrix [ECM]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0679—Cells of the gastro-intestinal tract
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03013—Protein-lysine 6-oxidase (1.4.3.13), i.e. lysyl-oxidase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
JP2020560900A 2018-05-03 2019-05-03 Ｉｌ－３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用 Active JP7548567B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024140826A JP2024159910A (ja) 2018-05-03 2024-08-22 Ｉｌ－３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666624P 2018-05-03 2018-05-03
US62/666,624 2018-05-03
PCT/US2019/030547 WO2019213482A1 (en) 2018-05-03 2019-05-03 Matrix bound vesicles (mbvs) containing il-33 and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024140826A Division JP2024159910A (ja) 2018-05-03 2024-08-22 Ｉｌ－３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2021523103A JP2021523103A (ja) 2021-09-02
JP2021523103A5 JP2021523103A5 (https=) 2022-04-27
JP7548567B2 true JP7548567B2 (ja) 2024-09-10

Family

ID=68386862

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020560900A Active JP7548567B2 (ja) 2018-05-03 2019-05-03 Ｉｌ－３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用
JP2024140826A Pending JP2024159910A (ja) 2018-05-03 2024-08-22 Ｉｌ－３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024140826A Pending JP2024159910A (ja) 2018-05-03 2024-08-22 Ｉｌ－３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用

Country Status (8)

Country Link
US (1) US12440444B2 (https=)
EP (1) EP3787642A4 (https=)
JP (2) JP7548567B2 (https=)
KR (1) KR20210005942A (https=)
CN (1) CN112805016A (https=)
AU (2) AU2019263479B2 (https=)
CA (1) CA3098149A1 (https=)
WO (1) WO2019213482A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015231110B2 (en) 2014-03-21 2019-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix
CA3049990A1 (en) 2017-03-02 2018-09-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Extracellular matrix (ecm) hydrogel and soluble fraction thereof for the treatment of cancer
EP3589292B1 (en) 2017-03-02 2023-08-23 University of Pittsburgh - Of the Commonwealth System of Higher Education Ecm hydrogel for treating esophageal inflammation
KR102872720B1 (ko) 2017-05-05 2025-10-16 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 기질 결합 소낭의 안구에의 적용
US20240226170A9 (en) * 2019-10-23 2024-07-11 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of mbv for treating autoimmune disease
JP2023514821A (ja) 2020-02-28 2023-04-11 テキサス メディカル センター 癒着阻止および組織治癒向上のための噴霧可能刺激応答性マイクロヒドロゲル
EP4135727A4 (en) * 2020-04-16 2024-05-22 University of Pittsburgh - of the Commonwealth System of Higher Education MATRIX-BOUND VESICLES (MBV) FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME
US20230210898A1 (en) * 2020-04-24 2023-07-06 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Microparticle-Assisted Treg Therapy for Treatment of Tissue Injury and Fibrosis
AU2023249793A1 (en) * 2022-04-08 2024-11-21 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Matrix bound nanovesicles encapsulated in hydrogels
EP4712988A1 (en) * 2023-05-17 2026-03-25 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for treating muscle wasting diseases using mbv
CN118416023B (zh) * 2024-05-07 2025-01-28 山东大学 用于特发性肺纤维化治疗的仿生纳米递送系统m@rcpda纳米粒及其制备方法
CN119033723B (zh) * 2024-08-15 2025-05-02 南京鼓楼医院 一种氨氯地平药物靶向递送系统及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518041A (ja) 2009-02-18 2012-08-09 コーマトリックス カーディオバスキュラー， インコーポレイテッド 心不整脈を予防するための組成物および方法
JP2013536246A (ja) 2010-08-24 2013-09-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心臓治療のための組成物及び方法
WO2016197038A1 (en) 2015-06-03 2016-12-08 Wisconsin Alumni Research Foundation Cardiac fibroblast-derived extracellular matrix and injectable formulations thereof for treatment of ischemic disease or injury
WO2017151862A1 (en) 2016-03-02 2017-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Matrix bound nanovesicles and their use

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4978668A (en) 1986-09-02 1990-12-18 Purdue Research Foundation Treatment to reduce ischemic tissue injury
US4956178A (en) 1988-07-11 1990-09-11 Purdue Research Foundation Tissue graft composition
US4902508A (en) 1988-07-11 1990-02-20 Purdue Research Foundation Tissue graft composition
US5007927A (en) 1989-10-24 1991-04-16 Purdue Research Foundation Muscle-powered cardiac assist device
US5281422A (en) 1991-09-24 1994-01-25 Purdue Research Foundation Graft for promoting autogenous tissue growth
US5352463A (en) 1992-11-13 1994-10-04 Badylak Steven F Tissue graft for surgical reconstruction of a collagenous meniscus and method therefor
US5275826A (en) 1992-11-13 1994-01-04 Purdue Research Foundation Fluidized intestinal submucosa and its use as an injectable tissue graft
US6653291B1 (en) 1992-11-13 2003-11-25 Purdue Research Foundation Composition and method for production of transformed cells
US5641518A (en) 1992-11-13 1997-06-24 Purdue Research Foundation Method of repairing bone tissue
US5695998A (en) 1995-02-10 1997-12-09 Purdue Research Foundation Submucosa as a growth substrate for islet cells
US6485723B1 (en) 1995-02-10 2002-11-26 Purdue Research Foundation Enhanced submucosal tissue graft constructs
WO1996031232A1 (en) 1995-04-07 1996-10-10 Purdue Research Foundation Tissue graft and method for urinary bladder reconstruction
US5711969A (en) 1995-04-07 1998-01-27 Purdue Research Foundation Large area submucosal tissue graft constructs
US5554389A (en) 1995-04-07 1996-09-10 Purdue Research Foundation Urinary bladder submucosa derived tissue graft
CA2160647C (en) 1995-10-16 2002-05-28 Thomas William Garay Helical bearing anchor catcher
US5755791A (en) 1996-04-05 1998-05-26 Purdue Research Foundation Perforated submucosal tissue graft constructs
DK0925067T3 (da) 1996-09-16 2004-05-03 Purdue Research Foundation Graft fra submucosavæv til reparation af neurologisk væv
WO1998019719A1 (en) 1996-11-05 1998-05-14 Purdue Research Foundation Myocardial graft constructs
DE69720252T2 (de) 1996-12-10 2003-12-04 Purdue Research Foundation, West Lafayette Gewebetransplantat aus der magensubmukosa
ATE249182T1 (de) 1996-12-10 2003-09-15 Purdue Research Foundation Rohrförmige transplantatkonstruktionen aus submucosalem gewebe
JP2001505807A (ja) 1996-12-10 2001-05-08 パーデュー・リサーチ・ファウンデーション 人工血管弁
JP4046358B2 (ja) 1996-12-10 2008-02-13 パーデュー・リサーチ・ファウンデーション 粘膜下組織抽出物
US6696270B2 (en) 1996-12-10 2004-02-24 Purdue Research Foundation Gastric submucosal tissue as a novel diagnostic tool
AU732726B2 (en) 1996-12-10 2001-04-26 Purdue Research Foundation Biomaterial derived from vertebrate liver tissue
WO2000015765A1 (en) 1998-09-11 2000-03-23 Purdue Research Foundation Enhanced submucosal tissue graft constructs
GB2361187A (en) 1998-12-01 2001-10-17 Purdue Research Foundation Submucosa modulation of mammalian immune response
US6918396B1 (en) 1998-12-01 2005-07-19 Purdue Research Foundation Method for vocal cord reconstruction
GB2360948B (en) 1998-12-01 2003-12-10 Purdue Research Foundation Composition suitable for vocal cord reconstruction
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6579538B1 (en) 1999-12-22 2003-06-17 Acell, Inc. Tissue regenerative compositions for cardiac applications, method of making, and method of use thereof
US20090053279A1 (en) 1999-12-22 2009-02-26 Badylak Stephen F Tissue regenerative composition
EP1503652A4 (en) 2002-05-02 2006-02-08 Purdue Research Foundation HYBRID GRAFTS WITH IMPROVED VASCULARIZATION
CN1665527A (zh) 2002-05-02 2005-09-07 普渡研究基金会 血管化增强的移植构造物
WO2003092381A1 (en) 2002-05-02 2003-11-13 Purdue Research Foundation Vascularization enhanced graft constructs
US20040191226A1 (en) 2002-12-04 2004-09-30 Badylak Stephen F. Method for repair of body wall
US20040187877A1 (en) 2002-12-04 2004-09-30 Badylak Stephen F. Method for repair of liver tissue
US20040176855A1 (en) 2003-03-07 2004-09-09 Acell, Inc. Decellularized liver for repair of tissue and treatment of organ deficiency
US20040175366A1 (en) 2003-03-07 2004-09-09 Acell, Inc. Scaffold for cell growth and differentiation
CA2530490A1 (en) 2003-06-25 2005-01-13 Stephen F. Badylak Conditioned matrix compositions for tissue restoration
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
WO2007084278A2 (en) 2006-01-06 2007-07-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Extracellular matrix based gastroesophageal junction reinforcement device
WO2008008266A2 (en) 2006-07-07 2008-01-17 University Of Pittsburgh- Of The Commonwealth System Of Higher Education Biohybrid elastomeric scaffolds and methods of use thereof
US8361503B2 (en) 2007-03-02 2013-01-29 University of Pittsburgh—of the Commonwealth System of Higher Education Extracellular matrix-derived gels and related methods
US20110184439A1 (en) 2008-05-09 2011-07-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biological Matrix for Cardiac Repair
WO2010099463A2 (en) 2009-02-27 2010-09-02 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Joint bioscaffolds
US9814744B2 (en) 2009-12-22 2017-11-14 University of Pittsburg—Of the Commonwealth System of Higher Education Decellularized adipose cell growth scaffold
US9421307B2 (en) 2010-08-17 2016-08-23 University of Pittsburgh—of the Commonwealth System of Higher Education Biohybrid composite scaffold
SG183579A1 (en) 2011-02-11 2012-09-27 Agency Science Tech & Res Methods of detecting therapeutic exosomes
WO2013009595A2 (en) 2011-07-08 2013-01-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Injectable cns-derived ecm for tissue reconstruction
ES2703785T3 (es) 2013-04-08 2019-03-12 Regentys Corp Método y composición para tratar una enfermedad inflamatoria intestinal sin colectomía
US9861662B2 (en) 2013-07-03 2018-01-09 University of Pittsburgh—of the Commonwealth System of Higher Education Bone-derived extra cellular matrix gel
US10286119B2 (en) 2014-01-24 2019-05-14 University of Pittsburgh—of the Commonwealth System of Higher Education Extracellular matrix mesh coating
AU2015231110B2 (en) 2014-03-21 2019-03-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Methods for preparation of a terminally sterilized hydrogel derived from extracellular matrix
WO2015164728A1 (en) 2014-04-24 2015-10-29 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Fractionating extracellular matrix to modulate bioactivity and the host response
DK3145493T3 (da) 2014-05-18 2022-10-31 Childrens Medical Center Fremgangsmåder og sammensætninger vedrørende exosomer
EP3319653A4 (en) 2015-07-10 2019-03-27 University of Pittsburgh - Of the Commonwealth System of Higher Education METHOD FOR PRODUCING ECM EQUIPMENT AND HYDROGELS FROM COLON
EP3347063B1 (en) 2015-09-10 2025-11-19 University of Pittsburgh - of the Commonwealth System of Higher Education Bi-layer extra cellular matrix scaffolds and uses therefor
EP3349814B1 (en) 2015-09-18 2021-03-17 University of Pittsburgh- Of the Commonwealth System of Higher Education Non-gelling soluble extracellular matrix with biological activity
CA3011294A1 (en) 2016-01-13 2017-07-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Vascular extracellular matrix hydrogel
JP2019513038A (ja) 2016-03-14 2019-05-23 リージェンティーズ コーポレイション 炎症性腸疾患を処置するための方法および組成物
EP3589292B1 (en) 2017-03-02 2023-08-23 University of Pittsburgh - Of the Commonwealth System of Higher Education Ecm hydrogel for treating esophageal inflammation
CA3049990A1 (en) 2017-03-02 2018-09-07 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Extracellular matrix (ecm) hydrogel and soluble fraction thereof for the treatment of cancer
US11389569B2 (en) 2017-04-03 2022-07-19 University of Pittsburgh—of the Commonwealth System of Higher Education Biodegradable, porous, thermally responsive injectable hydrogel as soft tissue defect filler
KR102872720B1 (ko) 2017-05-05 2025-10-16 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 기질 결합 소낭의 안구에의 적용

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012518041A (ja) 2009-02-18 2012-08-09 コーマトリックス カーディオバスキュラー， インコーポレイテッド 心不整脈を予防するための組成物および方法
JP2013536246A (ja) 2010-08-24 2013-09-19 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 心臓治療のための組成物及び方法
WO2016197038A1 (en) 2015-06-03 2016-12-08 Wisconsin Alumni Research Foundation Cardiac fibroblast-derived extracellular matrix and injectable formulations thereof for treatment of ischemic disease or injury
WO2017151862A1 (en) 2016-03-02 2017-09-08 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Matrix bound nanovesicles and their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Cytokine, 2012, Vol.58, p.368-379
Nat Med., 2012, Vol.18 No.7, p.1028-1040
Tissue Gngineering PartA, 2017, Vol.23 No.19, p.1152-1159
Tissue Gngineering PartA, 2017, Vol.23 Suppl.1, p.S-29(107)

Also Published As

Publication number Publication date
CA3098149A1 (en) 2019-11-07
US20210106526A1 (en) 2021-04-15
JP2021523103A (ja) 2021-09-02
AU2019263479B2 (en) 2026-01-08
AU2019263479A1 (en) 2021-01-07
AU2026202508A1 (en) 2026-04-23
JP2024159910A (ja) 2024-11-08
EP3787642A1 (en) 2021-03-10
KR20210005942A (ko) 2021-01-15
CN112805016A (zh) 2021-05-14
EP3787642A4 (en) 2022-09-21
US12440444B2 (en) 2025-10-14
WO2019213482A8 (en) 2020-11-05
WO2019213482A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
JP7548567B2 (ja) Ｉｌ－３３を含有するマトリックス結合型小胞（ｍｂｖｓ）およびそれらの使用
Goette et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation
US8147817B2 (en) IL-33 in the treatment and diagnosis of diseases and disorders
US9289489B2 (en) NOTCH inhibition in the treatment of cardiovascular disease
CN107405406A (zh) 用于治疗肺纤维化的血管紧张素ii受体激动剂
Goichberg et al. Age-associated defects in EphA2 signaling impair the migration of human cardiac progenitor cells
WO2004075852A2 (en) Compositions, combinations, and methods for treating cardiovascular conditions and other associated conditions
EP4125937A1 (en) Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
JP7691140B2 (ja) 自己免疫疾患を処置するためのｍｂｖの使用
JP5959800B2 (ja) グランザイムｂインヒビターを用いる解離，動脈瘤，およびアテローム性動脈硬化症の治療
West et al. Combined application of biosponges and an antifibrotic agent for the treatment of volumetric muscle loss
Zhang et al. Small-molecule integrated stress response inhibitor reduces susceptibility to postinfarct atrial fibrillation in rats via the inhibition of integrated stress responses
EP2531208A1 (en) Treatment of fibrosis-related disorders using fibronectin binding proteins and polypeptides
Chen et al. Human umbilical cord mesenchymal stem cells regulate CD54 and CD105 in vascular endothelial cells and suppress inflammation in Kawasaki disease
RU2728703C2 (ru) Композиции и способы для анти-lyst иммуномодуляции
Kale et al. Diabetes and cardiorenal complications: a clinical review of existing therapies and novel combinations, focusing on SGLT2 inhibitors
AU2012308097A1 (en) Treatment of bone diseases
CN114945672B (zh) 用于治疗心力衰竭的基因递送系统
Maejima et al. Synergistic Effect of Combined HMG-CoA Reductase Inhibitor and Angiotensin-II Receptor Blocker Therapy in Patients With Chronic Heart Failure–The HF-COSTAR Trial–
US20240293333A1 (en) Topical delivery of lipoprotein-mimetic nanoparticles
Ghali The role of interleukin-33 (IL-33) administration in cardiac function post-myocardial infarction
Kim et al. Relationships between serum uric acid level and coronary artery calcium score
Oh et al. Urolithin A Restores Mitochondrial Function and Reverses Cardiac Remodeling in HFpEF
Cho Physiological and Pharmacological Maneuvers to Rejuvenate Age-Associated Cardiovascular Dysfunction
Triastuti Pharmacological inhibition of the Hippo pathway in the cardiovascular system

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230217

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230426

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230802

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231026

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240703

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240822

R150 Certificate of patent or registration of utility model

Ref document number: 7548567

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150